The Wuhan National Bio-industry Base -- also known as the Biolake -- is China's second biggest state-level biotech industrial hub in terms of its overall strength.

It is located in Wuhan East Lake High-tech Development Zone, also known as the Optics Valley of China.

After 13 years of development, the bioindustry has become one of the pillar industries of Optics Valley. By the end of 2019, Optics Valley Biolake had attracted 3,000 companies to locate there.

At present, Biolake's seven industrial parks have formed an industrial cluster characterized by biomedicine, bio medical engineering, bio agriculture, precision medicine, smart medicine and bio services.

Currently, 30 Class I new drugs -- those that have never been marketed in China or overseas -- have entered the clinical stage.

Officials said that more than 500 Class I and II medical devices, 59 new veterinary drugs and 69 State-approved new varieties of crops have gone on the market -- and 149 products have entered the innovative products catalog of the city of Wuhan.

A number of leading medical device groups, including Mindray, United Imaging and BGI, have settled at Biolake in Optics Valley.

Officials said the settlement of the leading companies there with a scale of 10 billion yuan ($1.44 billion) to even 100 billion yuan -- and a number of leading enterprises and major projects at home and abroad -- has provided innovation support and vitality for the high-quality development of Optics Valley's bioindustry.